ArticleDiscover oncology2026
The clinical and pathological features of low-grade appendiceal mucinous neoplasm (LAMN).
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn this manuscript, we evaluated the clinicopathological features of low-grade appendiceal mucinous neoplasm (LAMN), a unique type of appendiceal tumors.
methodsThis is a retrospective study that included patients with LAMN who were presented to our center from January 2008 to December 2024. The epidemiological, clinical, pathological, therapeutic, and prognostic data were analyzed.
resultsA total of 68 patients were included in the study, with a median age of 55.8 years. Forty patients (58.8%) had pseudomyxoma peritonei (PMP) at the time of diagnosis. Surgical cytoreduction was used in 44 patients (65.7%), while appendectomy was performed in 23 patients (34.3%). HIPEC was used only in fifteen patients (22.4%). Gross perforation was identified in 7 cases (10.3%). While microscopically, micro-perforation or rupture was noted in 20 patients (29.4%). Adjuvant systemic treatment was used in 50% of the patients. Over a median follow-up of 18 months, recurrence occurred in 21 patients (31.8%), while five patients (7.4%) developed distant metastasis. Mortality rate was 20.5% (n=14), including five patients who died postoperatively, while nine showed tumor-related mortality. On univariate analysis, only adjuvant treatments showed statistically significant correlation with the incidence of recurrence (p=0.007).
conclusionsThe higher recurrence and mortality rates observed in our cohort compared with recent literature reflect the advanced disease burden and lower utilization of HIPEC. Future work should aim to refine patient selection for HIPEC, standardize operative approaches to minimize recurrence risk, and explore the role of adjuvant systemic therapy in reducing disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.